Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03904537
Other study ID # B2018-148-02
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 19, 2019
Est. completion date December 31, 2021

Study information

Verified date April 2019
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was a phase I/II trial initiated by the investigator to evaluate the safety and tolerability of anti-programmed cell death protein 1 (anti-PD1) antibody-activated autologous tumor-infiltrating lymphocytes (TILs) combined with adjuvant chemotherapy in participants with stage III colon cancer. Twenty participants were enrolled and anti-PD1 antibody-activated TILs was infused into participants after the final of adjuvant chemotherapy to assess the safety and 3-year disease-free survival.


Description:

Postoperative colon cancer participants received 4 to 8 cycles of XELOX regimen adjuvant chemotherapy and received anti-PD1 antibody-activated TILs on the day 15 of the final cycle of chemotherapy.

Fresh tumor tissues or sentinel lymph nodes were collected from participants with postoperative colon cancer, and the tumor tissues were digested with type IV collagenase at 37 °C for 2 to 4 hours. The cell pellet was washed, suspended in medium containing 10% AB serum, planted in a 24-well cell culture plate, and periodically changed according to the growth of the cells. After culturing for 2 to 3 weeks, TILs were co-stimulated with radioactively irradiated allogeneic peripheral blood mononuclear cells (PBMCs) and were expanded in 100 ml of Interleukin-2 (IL-2) medium in a cell culture flask. After rapid expansion for 15 days, the number of cells reached 0.1-1*10^10 cells. Before cell transfer, TILs were incubated with anti-PD-1 antibody, and a fraction of the TILs were collected to assess their number, phenotype, and viability of cells, and to test for possible contamination by bacteria, fungi, or endotoxins. Then, autologous TILs (0.1-1*10^10 cells) were transferred to participants via intravenous infusion.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 31, 2021
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Participants with stage III colorectal cancer and scheduled to receive adjuvant chemotherapy postoperation.

- Age 18 to 75 years.

- Willing to sign a durable power of attorney.

- Able to understand and sign the Informed Consent Document.

- Life expectancy of greater than six months.

- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving the preparative regimen.

- Adequate organ function.

- Serology:

Seronegative for HIV antibody. Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus.

•Hematology: white blood cell count (> 3500/mm(3)). Platelet count greater than 100,000/mm(3). Hemoglobin greater than 9.0 g/dl.

•Chemistry: Serum Alanine aminotransferase/Aspartate aminotransferase less or equal to 2.5 times the upper limit of normal.

Serum creatinine less than or equal to 1.6 mg/dl. Total bilirubin less than or equal to 1.5 mg/dl.

Exclusion Criteria:

- Previous treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) , anti-PD-1, and anti-Programmed death-ligand 1(PD-L1).

- Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.

- Allogeneic tissue/organ transplantation.

- Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).

- History of autoimmune disease

- Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).

- Concurrent antineoplastic therapies and systemic steroid therapy.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
anti-PD-1 antibody-activated TILs
Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy

Locations

Country Name City State
China Sun Yat-Sen University, Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-free survival (DFS) DFS is defined as the time from surgery until tumor recurrence or death. 6 months
Secondary Overall survival (OS) OS is defined as the time from surgery until death from any cause 6 months
Secondary Severity of adverse events According to National Cancer Institute Common Terminology Criteria for Adverse Events(NCI-CTCAE) 3 weeks
Secondary Immune cell subgroup and cytokine level The number and secreted cytokines of cluster of differentiation 3 (CD3+), CD8+, CD4+ or CD56+ T cells 1 months
Secondary The quality of life by EQ-5D-5L (EuroQol Group, Chinese versions ) Participants were interviewed with the EQ-5D-5L (EuroQol Group, Chinese versions). There are numbers from 0 to 100 on this scale of the EQ-5D-5L. 100 represents the best health condition you can imagine, and 0 represents the worst health condition in your imagination. Please put an X on the scale to indicate how healthy you are today. And the number you marked on the scale represents your health condition today. 3 weeks
See also
  Status Clinical Trial Phase
Completed NCT01570452 - Matrilysin Expression in Different Stages of Colorectal Tumors N/A
Active, not recruiting NCT04304209 - Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer Phase 2
Active, not recruiting NCT04398446 - Effect of Hemp-CBD on Patients With CIPN Phase 2
Recruiting NCT04486378 - A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer Phase 2
Recruiting NCT04264676 - Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer Phase 2
Recruiting NCT06314958 - Stage II/III Colorectal Cancer Recurrence
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting NCT04714814 - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Recruiting NCT05898789 - Virtual Rehabilitation for Cancer Survivors N/A
Completed NCT01356264 - Multimodal Prehabilitation for Colorectal Surgery Phase 2
Recruiting NCT04813627 - Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
Recruiting NCT03448549 - SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Phase 3
Not yet recruiting NCT05131243 - the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer N/A
Recruiting NCT06076811 - DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
Recruiting NCT06111105 - Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Recruiting NCT06342401 - Early Onset Colorectal Cancer Detection
Completed NCT06271980 - Early-Onset Colorectal Cancer Recurrence